Aequus Pharmaceuticals Inc.

AQS

CA0076361033

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 09:30:00 2025-04-25 am EDT			5-day change	1st Jan Change
0.005000 ^CAD	-.--%		-.--%	-50.00%

May. 22	Luvo Medical Technologies Inc. signed an asset purchase agreement to acquire Zimed® PF from Aequus Pharmaceuticals Inc. for CAD 0.40 million.	CI
May. 21	Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 05/21/2025 at 23:35

Aequus Pharmaceuticals Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was CAD 0.645101 million compared to CAD 0.662088 million a year ago.

Latest news about Aequus Pharmaceuticals Inc.

Luvo Medical Technologies Inc. signed an asset purchase agreement to acquire Zimed® PF from Aequus Pharmaceuticals Inc. for CAD 0.40 million.	May. 22	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 21	CI
Aequus Pharmaceuticals Inc. Announces Resignation of Anne Stevens and Chris Clark as Directors, Effective April 25, 2025	Apr. 24	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Apr. 24	CI
Aequus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	Apr. 24	CI
Aequus Pharmaceuticals Inc. Announces Resignation of Ann Fehr as CFO	Nov. 08	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 08	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-30	CI
Aequus Pharmaceuticals Inc. Signs Exclusive Distribution Agreement with Advanced Ophthalmic Innovations for the Paul® Glaucoma Drainage Device in Canada	24-07-02	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-09	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	24-04-30	CI
Aequus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	24-04-29	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-11-28	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Aequus Says Zimed PF Now Available in Canada	23-08-24	MT
Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada	23-08-24	CI
Aequus Pharmaceuticals Announces Zimed PF Website Launch	23-08-22	MT
Aequus Pharmaceuticals Pauses Sales Of Evolve Intensive Eyedrops, Gel in Canada	23-08-18	MT
Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada	23-08-18	CI
Aequus Pharmaceuticals Announcds Financing to Support Launch of Zimed Preservative Free	23-07-07	MT
Aequus Pharmaceuticals Inc. Increases Its Debt by $400,000 to Support the Launch of Zimed Pf	23-07-05	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Aequus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	23-04-30	CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-30	CI
Aequus Pharmaceuticals Inc. Announces the Resignation of Stuart Fowler from the Board of Directors	23-04-05	CI

Chart Aequus Pharmaceuticals Inc.

Duration

Period

AQS: Dynamic Chart

Company Profile

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patientâs eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.

Employees

Sector

Pharmaceuticals

Calendar

Aug. 31 - Q2 2025 Earnings Release (Projected)

More about the company